CD38 and neoplasm: CD38 and CD123 may also be two important targets for refractory/relapsed ALL, as the former could reduce on-target off-tumor effects and the latter shows a strong anti-tumor effect on CD19-negative ALL mice in preclinical trials [41, 43].